Neonatal respiratory distress syndrome (RDS) remains a leading cause of morbidity and mortality in preterm infants. This condition stems primarily from an insufficiency in pulmonary surfactant, a ...
Please provide your email address to receive an email when new articles are posted on . Minimally invasive surfactant therapy did not lower mortality among preterm infants with respiratory distress ...
Objective: The aim of the study was to measure pulmonary mechanics in infants with respiratory distress syndrome before extubation and to correlate pulmonary function values with successful extubation ...
The Lundquist Institute (TLI) and The Bill & Melinda Gates Medical Research Institute (Gates MRI) executed a license agreement for TLI intellectual property covering a synthetic lung surfactant ...
LA JOLLA, CA - Scientific advances at The Scripps Research Institute have led to a new drug Surfaxin® (lucinactant), approved today by the U.S. Food and Drug Administration (FDA) to treat infant ...
HealthDay News — The FDA has approved Surfaxin (lucinactant) to prevent respiratory distress syndrome (RDS) in premature infants. Premature infants born before 37 weeks’ gestation often cannot produce ...
Holly Jordan's premature son survived — thanks to medical advances after Patrick Kennedy's death from Infant Respiratory Distress Syndrome decades earlier Holly Jordan, who works in business ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results